Literature DB >> 11476982

Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients.

T J Kang1, G T Chae.   

Abstract

Toll-like receptor 2 (TLR2) is critical in the immune response to mycobacterial infections and the mutations in the TLR2 have been shown to confer the susceptibility to severe infection with mycobacteria. To define this, we screened the intracellular domain of TLR2 in 131 subjects. Groups of 45 lepromatous and 41 tuberculoid leprosy (TT) patients and 45 controls were investigated. Ten subjects among the lepromatous leprosy (LL) patients had a band variant detected by single-stranded conformational polymorphism. DNA sequencing detected a C to T substitution at nucleotide 2029 from the start codon of the TLR2. The mutation would substitute Arg to Trp at amino acid residue 677, one of the conserved regions of TLR2. In our results, the mutation was involved in only LL, not TT and control. Thus, we suggest that the mutation in the intracellular domain of TLR2 has a role in susceptibility to LL.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11476982     DOI: 10.1111/j.1574-695X.2001.tb01586.x

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  67 in total

1.  Anti-cyclic citrullinated peptide antibodies and rheumatoid factor sera titers in leprosy patients from Mexico.

Authors:  María G Zavala-Cerna; Mary Fafutis-Morris; Cecilia Guillen-Vargas; Mario Salazar-Páramo; Diana E García-Cruz; Carlos Riebeling; Arnulfo Nava
Journal:  Rheumatol Int       Date:  2011-11-15       Impact factor: 2.631

2.  Different patterns of Toll-like receptor 2 polymorphisms in populations of various ethnic and geographic origins.

Authors:  M Ioana; B Ferwerda; T S Plantinga; M Stappers; M Oosting; M McCall; A Cimpoeru; F Burada; N Panduru; R Sauerwein; O Doumbo; J W M van der Meer; R van Crevel; L A B Joosten; M G Netea
Journal:  Infect Immun       Date:  2012-02-21       Impact factor: 3.441

3.  A novel aminosaccharide compound blocks immune responses by Toll-like receptors and nucleotide-binding domain, leucine-rich repeat proteins.

Authors:  Kyoung-Hee Lee; Yuen-Joyce Liu; Amlan Biswas; Chikako Ogawa; Koichi S Kobayashi
Journal:  J Biol Chem       Date:  2010-12-07       Impact factor: 5.157

Review 4.  Leprosy as a genetic disease.

Authors:  Andrea Alter; Audrey Grant; Laurent Abel; Alexandre Alcaïs; Erwin Schurr
Journal:  Mamm Genome       Date:  2010-10-09       Impact factor: 2.957

5.  Lack of association between Toll-like receptor 2 polymorphisms and susceptibility to severe disease caused by Staphylococcus aureus.

Authors:  Catrin E Moore; Shelley Segal; Anthony R Berendt; Adrian V S Hill; Nicholas P J Day
Journal:  Clin Diagn Lab Immunol       Date:  2004-11

6.  TLR-2 gene Arg753Gln polymorphism is strongly associated with acute rheumatic fever in children.

Authors:  Afig Berdeli; Handan Ak Celik; Ruhi Ozyürek; Buket Dogrusoz; Hikmet Hakan Aydin
Journal:  J Mol Med (Berl)       Date:  2005-06-21       Impact factor: 4.599

Review 7.  Toll-like receptors in defense and damage of the central nervous system.

Authors:  Rajagopal N Aravalli; Phillip K Peterson; James R Lokensgard
Journal:  J Neuroimmune Pharmacol       Date:  2007-04-03       Impact factor: 4.147

8.  High prevalence of the CD14-159CC genotype in patients infected with severe acute respiratory syndrome-associated coronavirus.

Authors:  Fang F Yuan; Ingrid Boehm; Paul K S Chan; Katherine Marks; Julian W Tang; David S C Hui; Joseph J Y Sung; Wayne B Dyer; Andrew F Geczy; John S Sullivan
Journal:  Clin Vaccine Immunol       Date:  2007-10-03

Review 9.  Pathogen recognition and inflammatory signaling in innate immune defenses.

Authors:  Trine H Mogensen
Journal:  Clin Microbiol Rev       Date:  2009-04       Impact factor: 26.132

10.  Toll-like receptors TLR4 (Asp299Gly and Thr399Ile) and TLR2 (Arg677Trp and Arg753Gln) gene polymorphisms in end-stage renal disease patients on peritoneal dialysis.

Authors:  Kamini Singh; Kashi Nath Prasad; Priyanka Mishra; Jahanarah Khatoon; Narayan Prasad; Amit Gupta; Janmejai Kumar Srivastava
Journal:  Int Urol Nephrol       Date:  2015-10-22       Impact factor: 2.370

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.